Advaxis (NASDAQ:ADXS) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.
Volatility & Risk
Advaxis has a beta of 3.94, indicating that its stock price is 294% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of -1.13, indicating that its stock price is 213% less volatile than the S&P 500.
This table compares Advaxis and Clearside Biomedical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation & Earnings
This table compares Advaxis and Clearside Biomedical’s revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Advaxis||$6.06 million||4.91||-$66.51 million||($1.29)||-0.33|
|Clearside Biomedical||$30,000.00||1,515.80||-$58.97 million||($2.69)||-0.53|
Clearside Biomedical has lower revenue, but higher earnings than Advaxis. Clearside Biomedical is trading at a lower price-to-earnings ratio than Advaxis, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
22.5% of Advaxis shares are held by institutional investors. Comparatively, 39.9% of Clearside Biomedical shares are held by institutional investors. 3.0% of Advaxis shares are held by company insiders. Comparatively, 15.4% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings and target prices for Advaxis and Clearside Biomedical, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Advaxis currently has a consensus target price of $2.00, suggesting a potential upside of 368.38%. Clearside Biomedical has a consensus target price of $11.83, suggesting a potential upside of 733.33%. Given Clearside Biomedical’s stronger consensus rating and higher possible upside, analysts plainly believe Clearside Biomedical is more favorable than Advaxis.
Clearside Biomedical beats Advaxis on 8 of the 14 factors compared between the two stocks.
Advaxis Company Profile
Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Clearside Biomedical Company Profile
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to treat blinding diseases of the eye. It is developing suprachoroidal injection of CLS-TA, a proprietary preservative-free formulation of the corticosteroid triamcinolone acetonide, which is in Phase III clinical trial for the treatment of macular edema associated with non-infectious uveitis; suprachoroidal injection of CLS-TA and a concomitant intravitreal injection of Eylea, an inhibitor of vascular endothelial growth factor that is in Phase III clinical trial to treat macular edema associated with retinal vein occlusion; and suprachoroidal injection of CLS-TA alone or together with intravitreal injection of Eylea that is in phase II clinical trial for diabetic macular edema. The company also engages in the development of therapies in various areas, such as gene therapy for inherited retinal disorders, neovascular age-related macular degeneration, and other ocular diseases. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.